29 August 2017 ALA-induced protoporphyrin IX flurokinetics in dermatological disease states monitored by surface-detected fluorescence
Author Affiliations +
Proceedings Volume 10313, Opto-Canada: SPIE Regional Meeting on Optoelectronics, Photonics, and Imaging; 103132T (2017) https://doi.org/10.1117/12.2283897
Event: Opto-Canada: SPIE Regional Meeting on Optoelectronics, Photonics, and Imaging, 2002, Ottawa, Ontario, Canada
Abstract
Photodynamic therapy (PDT) is a relatively new methodology currently being investigated for use in the treatment of cancerous or abnormal tissue. The principle of PDT relies on a photosensitizer that is administered to the patient, then photoexcited to induce a cytotoxic reaction. To be a useful drug for PDT, a photosensitizer should show specific properties. These include a preferential accumulation in abnormal tissue compared to normal tissue, a fast clearance time, a strong absorption in the red or near infrared region of the electromagnetic spectrum, and finally a toxicity in the presence of light but harmless otherwise.
© (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Albane Sibourd-Baudry, Albane Sibourd-Baudry, } "ALA-induced protoporphyrin IX flurokinetics in dermatological disease states monitored by surface-detected fluorescence", Proc. SPIE 10313, Opto-Canada: SPIE Regional Meeting on Optoelectronics, Photonics, and Imaging, 103132T (29 August 2017); doi: 10.1117/12.2283897; https://doi.org/10.1117/12.2283897
PROCEEDINGS
3 PAGES


SHARE
Back to Top